Levaquin Lawsuit Update: Monthly Status Conference Convened in Federal Fluoroquinolone Peripheral Neuropathy Litigation, Bernstein Liebhard LLP Reports
June 08, 2016 (PRLEAP.COM) Business NewsJune 8, 2016 - Nearly 400 peripheral neuropathy lawsuits (http://www.rxinjuryhelp.com/levaquin/peripheral-neuropathy/) filed against the manufacturers of Levaquin, Cipro and Avelox continue to move forward in the federal multidistrict litigation now underway in the U.S. District Court, District of Minnesota. Court records indicate that the proceeding convened its most recently monthly Status Conference on May 18th, at which time it was reported that 383 cases were pending in the federal litigation. An addition 39 claims that put forth similar allegations regarding the potential for fluoroquinolone antibiotics to cause peripheral neuropathy and permanent nerve damage have been filed in the Philadelphia Court of Common Pleas. Minutes from the federal conference indicate that the Pennsylvania judge overseeing those cases would be interested in coordinating with the multidistrict litigation. (In Re: Fluoroquinolone Products Liability Litigation – MDL No. 2642)
The Minutes also indicated that Plaintiffs have submitted a proposed bellwether case protocol to the Court. A response from the Defendants will be due in September.
"Our Firm is representing individuals in Levaquin lawsuits and other fluoroquinolone peripheral neuropathy claims. We are pleased that these cases are moving forward, and will continue to monitor the federal litigation for any developments that could impact our clients' cases," says Sandy A. Liebhard LLP, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free, no-obligation legal reviews to patients who were diagnosed with peripheral neuropathy that could be associated with the use of Levaquin, Cipro or Avelox.
Fluoroquinolone Side Effects
Fluoroquinolone antibiotics, including Levaquin, Cipro and Avelox, are indicated to treat pneumonia, sexually transmitted diseases, E. coli, staph and other serious bacterial infections. Plaintiffs who have Levaquin lawsuits or other cases pending in the District of Minnesota claim that the manufacturers of these medications failed to provide doctors and patients with adequate warnings about their potential to cause serious nerve damage, including permanent peripheral neuropathy. Mention of these complications was added to the drugs' labeling in 2004. However, the U.S. Food & Drug Administration (FDA) ordered their manufacturers to strengthen the labels in 2013 to better reflect the rapid onset of symptoms, as well as the potential for permanence. (In Re: Fluoroquinolone Products Liability Litigation – MDL No. 2642)
Last month, the FDA ordered that further modifications be made to the labels for fluoroquinolone medications, this time updating the boxed warning to state that the risks posed by the drugs outweigh their benefits for patients with certain uncomplicated infections when other treatment options are available. The agency acted after a review confirmed that fluoroquinolone antibiotics are associated with a number of serious side effects, including those involving the tendons, muscles, joints, nerves and central nervous system. These complications are potentially permanent and can occur together, the FDA said.
Patients who were diagnosed with peripheral neuropathy or permanent nerve damage following treatment with Levaquin, Cipro or Avelox may be entitled to file a claim of their own. To learn more about filing a Levaquin lawsuit, please visit Bernstein Liebhard LLP's website. Free, no-obligation legal consultations can also be obtained by calling 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2016 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP